



FACULDADE DE MEDICINA  
UNIVERSIDADE DO PORTO

## MESTRADO INTEGRADO EM MEDICINA

2013/2014

Joana dos Santos Frasco

Prospective evaluation of limited joint mobility in type 1

Diabetes Mellitus: from adolescence to adulthood

março, 2014

FMUP



FACULDADE DE MEDICINA  
UNIVERSIDADE DO PORTO

Joana dos Santos Frasco  
Prospective evaluation of limited joint mobility in type 1  
Diabetes Mellitus: from adolescence to adulthood

**Mestrado Integrado em Medicina**

**Área: Pediatria**

**Trabalho efetuado sob a Orientação de:  
Dr.<sup>a</sup> Marta João Rodrigues Silva**

**E sob a Coorientação de:  
Doutora Paula Isabel Marques Simões de Freitas**

**Trabalho organizado de acordo com as normas da revista:  
Diabetes Care**

março, 2014

**FMUP**

Eu, **Joana dos Santos Frasco**, abaixo assinado, nº mecanográfico **200806659**, estudante do 6º ano do Ciclo de Estudos Integrado em Medicina, na Faculdade de Medicina da Universidade do Porto, declaro ter atuado com absoluta integridade na elaboração deste projeto de opção.

Neste sentido, confirmo que **NÃO** incorri em plágio (ato pelo qual um indivíduo, mesmo por omissão, assume a autoria de um determinado trabalho intelectual, ou partes dele). Mais declaro que todas as frases que retirei de trabalhos anteriores pertencentes a outros autores, foram referenciadas, ou redigidas com novas palavras, tendo colocado, neste caso, a citação da fonte bibliográfica.

Faculdade de Medicina da Universidade do Porto, 20/03/2014

Assinatura conforme cartão de identificação:

Joana dos Santos Frasco

NOME

Joana dos Santos Frasco

CARTÃO DE CIDADÃO

13768827

E-MAIL

mimed08115@med.up.pt

TELEFONE OU TELEMÓVEL

914744120

NÚMERO DE ESTUDANTE

200806659

DATA DE CONCLUSÃO

20 de Março de 2014

DESIGNAÇÃO DA ÁREA DO PROJECTO

Pediatria

TÍTULO DISSERTAÇÃO

Prospective evaluation of limited joint mobility in type 1 Diabetes Mellitus: from adolescence to adulthood

ORIENTADOR

Dr.ª Marta João Rodrigues Silva

COORIENTADOR

Doutora Paula Isabel Marques Simões de Freitas

É autorizada a reprodução integral desta Dissertação para efeitos de investigação e de divulgação pedagógica, em programas e projectos coordenados pela FMUP.

Faculdade de Medicina da Universidade do Porto, 20/03/2014

Assinatura conforme cartão de identificação:

Joana dos Santos Frasco

## Dedicatória

Aos meus pais, ao meu irmão e a todos os meus familiares. Ao Diogo. A todos os meus amigos.

*A ti, Esperança.*

A ti, que nos dás força,  
A ti, que nos impões simplicidade.  
A ti, que nos acordas  
e com o rosto sereno  
nos ergues de manhã.  
A ti, que nada pedes  
a não ser um pouco de música  
e nada exiges  
e nos dás a tua própria ternura.  
A ti, que diariamente nos acolhes  
e nos trazes riso fresco  
e nos dás uvas  
e nos fazes cantar nas horas difíceis.  
A ti, que ofereces água  
a todos que passam  
e mostras um caminho  
aos poucos iluminados.  
A ti, que com a tua dança,  
o teu ritmo, o teu fogo  
transformas as paisagens  
e deixas ruas cor de ouro  
e deixas árvores cor de linho.  
A ti, que estás suspensa na noite  
como uma lua branca,  
e nos enches com a tua claridade  
e nos dás esta grande confiança,  
esta alegria imensa de crianças.  
A ti esperança, eu dedico  
agora e sempre  
este poema.

João Rui de Sousa

**Prospective evaluation of limited joint mobility in type 1 Diabetes Mellitus:  
from adolescence to adulthood**

Limited joint mobility in type 1 diabetes

Joana Frasco <sup>1</sup>

Marta Silva, MD <sup>2</sup>

Paula Freitas, MD, Ph.D. <sup>3</sup>

<sup>1</sup> University of Porto Medical School

<sup>2</sup> University of Porto Medical School, Pediatrics Department of Centro Hospitalar São João

<sup>3</sup> University of Porto Medical School, Endocrinology, Diabetes and Metabolism Department  
of Centro Hospitalar São João

Corresponding author: Joana S. Frasco; Alameda Hernâni Monteiro, 4200, Porto, Portugal;  
914744120; mimed08115@med.up.pt

Word count: 3978 words

Number of tables: 3

Number of figures: 1

**OBJECTIVE:** To study the longitudinal relationship of limited joint mobility (LJM) expression, severity and evolution with glycemic control and to determine its association with retinopathy and albuminuria in type 1 diabetic patients.

**RESEARCH DESIGN AND METHODS:** A total of 26 type 1 diabetic adolescents aged 13-18 years and with a disease duration  $\geq 5$  years were prospectively followed between 2007-2013 with repeated measurements of HbA<sub>1c</sub> levels and assessments of retinopathy and albuminuria. Retrospective HbA<sub>1c</sub> levels were also obtained. LJM was assessed twice, once in 2007 and again in 2013.

**RESULTS:** Overall prevalence of LJM was 85%. Prevalence of each LJM stage significantly changed between the two evaluations ( $p=0.049$ ); 69% of the patients showed a regression/maintained their initial stage while 31% progressed to a severer one. Progression group had higher mean HbA<sub>1c</sub> levels than the regression/no-evolution group ( $9.8 \pm 1.3$  vs  $8.6 \pm 1.2\%$ ,  $p=0.03$ ). Patients with final stage  $\geq 2$  had higher mean HbA<sub>1c</sub> than stage-0 ( $9.9 \pm 0.9$  vs  $8.6 \pm 0.7\%$ ,  $p=0.01$ ) and than stage-1 patients ( $9.9 \pm 0.9$  vs  $8.2 \pm 0.9\%$ ,  $p=0.01$ ). Both presence and evolution of LJM weren't significantly associated with retinopathy and albuminuria.

**CONCLUSIONS:** Severer stages and progression of LJM are associated with poorer glycemic control in adolescents and young adults with type 1 diabetes. Inclusion of LJM assessment in the follow-up routine should be considered, especially in these patients. Larger longitudinal studies with several evaluations of LJM are fundamental to evaluate more fully its clinical course and association with glycemic control and microvascular complications.

Type 1 Diabetes Mellitus is a chronic disease associated with significant morbidity not only due to the extensively known and studied micro and macrovascular complications but also due to its several rheumatic and musculoskeletal manifestations (1; 2). Among these manifestations the most frequent are those affecting the upper limb, specially the hands (2) and so the term “diabetic hand” has arisen, encompassing a range of conditions that affect the hands of diabetic patients including limited joint mobility (LJM) in first place but also Dupuytren's contracture, flexor tenosynovitis and others (3).

LJM is the first clinically apparent long-term complication of type 1 diabetes (4). It affects primarily the hands and is characterized by painless, non-inflammatory limitation of extension of the finger joints in association with thick and waxy skin, particularly on their dorsal surface. The onset of LJM is insidious; it usually begins in the fifth finger and then progresses radially with hands being symmetrically affected in most of the cases. The first and most frequently limited joints are the proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints; gradually, it can start to affect metacarpophalangeal (MCP) joints and, in later stages, may extend beyond the hands to peripheral large joints of both upper and lower limbs as wrists, elbows, knees, ankle and inclusive to spine (5-9). The diagnosis of this condition is essentially clinical and can be made with the help of two clinical signs: the “prayer sign” and the “tabletop test” (5; 7; 10). Laboratory, imaging, and nail fold capillaroscopy findings are usually unremarkable or nonspecific (5; 8).

LJM was first reported as particularly associated with juvenile type 1 diabetes by Rosenbloom in 1974 (11) and it was only since then that larger studies on this topic started to be conducted, corroborating these findings (6; 8). The estimated prevalence of LJM among diabetic patients varies widely according to different authors, ranging from 8 to 58% in type 1 diabetes (2) but it's often suggested at between 30 and 40% by most studies (8). There is also significant evidence that the frequency of LJM increases with increasing diabetes duration (12-

14), with pre-pubertal onset of diabetes (15) and with puberty (16), being more common between the ages of 10 and 20 and rare before the age of 10 (2; 4). Moreover, no gender or racial differences have been found (8; 10).

The early recognition of this condition is important because there is some evidence that it is associated with poor glycemic control (13; 16; 17) and with diabetic microvascular complications (13; 14; 16; 18-20). However, most of the studies focused on these topics are cross-sectional, with only a few of them having a prospective design. Moreover, in most of the cases, results are conflicting and therefore many questions still with no conclusive answer. For instance, whether careful glycemic control can prevent the onset of LJM or improve/stabilize the LJM already established is unknown; similarly, the extent to which LJM serves as an early marker of ongoing retinopathy/nephropathy has not been conclusively determined (2; 8).

The current study aims to determine the longitudinal relationship of LJM presence and severity with glycemic control in type 1 diabetic patients and to understand the extent to which the evolution of LJM depends on glycemic control. It also pretends to evaluate the association of LJM with retinopathy and albuminuria.

## **RESEARCH DESIGN AND METHODS**

We conducted a longitudinal prospective study with beginning in 2007 and ending in 2013, in a total of 6 years of follow-up.

Consecutive type 1 diabetic patients were recruited from the pediatric endocrinology outpatient consultation of Centro Hospitalar São João during over a one year period. Patients must had a documented date of diabetes diagnosis and should be followed in this hospital's consultation from soon after that time in order to have reliable retrospective data. Only patients aged between 13 and 18 and with a disease duration of 5 or more years were included. All the

other patients were excluded as well as those who had a history of hand injury, Dupuytren's contracture, flexor tenosynovitis or any other hand disorder that could misunderstand the evaluation of LMJ. With this criteria, we were able to recruit 46 patients into the study by 2007. However, due to hospital transfers or repeated absences to scheduled appointments, there were some subjects lost to follow-up which were excluded from the final sample. In the end, we counted with a total of 26 patients.

Information about patient's age, duration of diabetes, age of diagnosis, HbA<sub>1c</sub> levels, status of retinopathy and albuminuria were recorded for each patient in 2007 first evaluation. All retrospective information needed was obtained from medical files. During the follow-up time, patients visited the hospital every two to four months in the context of their routine outpatient follow-up and updated information about HbA<sub>1c</sub> levels, retinopathy and albuminuria status were also recorded.

Joint mobility was only assessed twice, once in 2007 and again in 2013. There were no retrospective information about it for any of the patients. The observer was the same for all patients within the same year but different between the two evaluations. Nevertheless, the exactly same methods were used and last examiner was blinded to previous results. The "tabletop test" and "prayer sign" were performed subsequently to assess joint mobility. The "prayer sign" was positive if the patient was unable to completely approximate the palmar surface of the hands and fingers when asked to raise the hands in a praying position with the fingers fanned and wrists extended (5; 18; 21). The "tabletop test" was positive if the patient was unable to make contact of the entire palmar surface to a table when asked to flatten the palm of his hand with the fingers fanned against the table's surface (5; 8; 22). Metacarpophalangeal joint contractures were detected by asking the patient to lift the palm from the table while keeping the fingers on it (15). When one or both of these maneuvers were positive, the examiner confirmed the limited mobility by attempting to extend the fingers

passively; there was a loss of passive extension if the range of extension was less than 180° at the PIP and DIP joints, less than 60° at the MCP joints and less than 70° at wrist (5; 7; 18). Joint mobility was staged from 0 to 3 based on the classification of Grgic et al. (22) - stage 0: entire palmer surface contacts with the table and there is no limitation; stage 1: only one finger of one or both hands is affected; stage 2: two or more fingers of each hand are affected; stage 3: all fingers of both hands plus some larger joint (wrist) are affected. Comparing the first evaluation's stage with the last one, patients were included in one of three groups: regression (if initial stage > last stage), no-evolution (if initial stage = last stage) and progression (if initial stage < last stage). Overall, patients were included in "with LJM" group if they presented limitation of joint mobility in any of the two evaluations; the remainder were included in "without LJM" group.

Glycemic control was measured by HbA<sub>1c</sub> levels. All its retrospective determinations from soon after diagnosis of diabetes were recorded. During follow-up time, HbA<sub>1c</sub> levels were determined from blood samples taken during outpatient visits. At least two measurements were recorded per year per patient.

Retinopathy status was determined annually by a trained ophthalmologist and considered to be present if it was diagnosed in any of its forms (non-proliferative or proliferative).

Albuminuria status was determined by measurement of the albumin excretion and albumin/creatinine ratio (ACR) in random spot urine collections. A patient was considered to have developed increased urinary albumin excretion (Albuminuria+) only if more than two consecutive specimens collected were abnormal (ACR  $\geq$ 30 mg/g creatinine) and were then confirmed by an abnormal 24h urine analyses ( $\geq$ 30 mg/24h). Both persistent albuminuria (at levels 30–299 mg/24h and levels >300 mg/24h) and transient albuminuria were included in the same category (23). Isolated abnormal ACR and 24h albumin excretion <30 mg/24 h were considered normal.

Ethical approval was obtained from ethical committee of the Centro Hospitalar São João. Adolescents were asked to assent before entering the study and oral informed consent was obtained from the parents prior to their inclusion. Written consent was also obtained from patients in the second LJM evaluation in 2013.

### **Statistical analyses**

All continuous variables were assessed for their normality using Shapiro-Wilk normality test. Normally distributed data are expressed as means  $\pm$  SE; otherwise the median (range) is used. Differences in normal continuous variables between groups were analyzed using the parametric tests Independent Samples T Test, Paired-Samples T Test or One-way ANOVA with Bonferroni correction for post-hoc testes when necessary. When parametric tests' assumptions were not verified or variables didn't follow a normal distribution, comparison between groups were done using non-parametric Mann Whitney U Test. Chi-square testing allowed comparisons between categorical variables. In some analysis, data from groups with LJM stages 2 and 3 as well as from regression and no-evolution group were combined. IBM SPSS Statistics version 21 was used for analysis. A p-value  $<0.05$  was considered significant.

## **RESULTS**

### **Demographic and clinical characteristics of the sample**

A total of 26 patients (14 males and 12 females) with type 1 diabetes meeting the inclusion and follow-up criteria were included in the statistical analyses. Characteristics of the sample at the beginning of the study are shown in Table 1. The mean age of the patients was  $14.9 \pm 1.6$  years with a median duration of diabetes of 7.5 years (range 5-14). In terms of clinical characteristics, the mean HbA<sub>1c</sub> of the sample was  $9.3 \pm 1.4\%$  ( $78 \pm 15.3$  mmol/mol); none of the patients had documented retinopathy at the time and just 2 had evidence of

albuminuria. All patients were followed during the 6-years period from 2007 to 2013. By the end of the study, all patients had already reached adulthood; the mean HbA<sub>1c</sub> was  $9.1 \pm 1.1\%$  ( $76 \pm 12.0$  mmol/mol), retinopathy was present in 39% (n=10) of the patients and albuminuria in 27% (n=7).

### **LJM prevalence, staging and evolution**

The prevalence of LJM (stage>0) in 2007 was 58% (n=15) compared with 70% (n=19) in 2013. The distribution of LJM stages significantly changed between the two evaluations: stage-0 prevalence decreased from 42 to 27%; stage-1 increased from 23 to 27%; stage-2 increased from 19 to 35% and stage-3 decreased from 15 to 12% (p=0.049). Patients with the same initial stage showed different evolutions during the follow-up time, being able to present a less or a more severe final stage than the initial one (Figure 1). In a global view, 69% of patients showed a regression or maintained the initial stage while 31% progressed to a more severe one. The characteristics of each evolution group are listed in Table 2. The median diabetes duration, age as well as the gender distribution wasn't statistically different between the two groups.

By the end of the study, patients with LJM represented 85% (n=22) of the sample and those without LJM represented the remaining 15% (Table 3). As for the evolution groups, no differences in diabetes duration, age and gender distribution were observed between patients with and without LJM.

### **Relation of LJM presence, evolution and severity to glycemc control**

Mean HbA<sub>1c</sub> levels during the follow-up period were significantly higher in those patients of the progression group compared to those of the regression/no-evolution group ( $9.8 \pm 1.3$  vs  $8.6 \pm 1.2\%$ , p=0.03) ( $84 \pm 14.2$  vs  $70 \pm 13.1$  mmol/mol). Similar findings were observed within the groups of patients with the same initial stage: for a given initial stage, patients who

regressed to a less severe stage had lower mean HbA<sub>1c</sub> levels during the follow-up than those who maintained or progressed to a severer one; similarly, patients who maintained the same stage had lower levels than those who progressed (data not shown). However, these differences were not significant for any of the four initial stages. Using the mean of all HbA<sub>1c</sub> values recorded until 2013 instead of using those recorded only during the follow-up period, similar comparisons reached significance and revealed overlapping results: HbA<sub>1c</sub> levels were significantly higher in patients initially 0-staged that progressed to stage-1/stage-2 comparing with those who didn't ( $10.1 \pm 1.0$  vs  $8.7 \pm 0.7\%$ ,  $p=0.04$ ) ( $87 \pm 10.9$  vs  $72 \pm 7.7$  mmol/mol) and in patients initially 2-staged who remained in that stage compared with those who regressed to a less severe stage ( $9.3 \pm 0.3$  vs  $8.0 \pm 0.3\%$ ,  $p=0.01$ ) ( $78 \pm 3.3$  vs  $64 \pm 3.3$  mmol/mol). These differences were also observed for initial stage-3 group but statistical conclusions were not possible due to small numbers.

Comparing the mean HbA<sub>1c</sub> levels until 2007 with the mean HbA<sub>1c</sub> levels during the follow-up period, in the regression/no-evolution group these values decreased from  $9.1 \pm 1.5$  to  $8.6 \pm 1.2\%$  ( $76 \pm 16.4$  to  $70 \pm 13.1$  mmol/mol) and in the progression group increased from  $9.5 \pm 1.3$  to  $9.8 \pm 1.2\%$  ( $80 \pm 14.2$  to  $84 \pm 13.1$  mmol/mol); however, these differences were not significant in any of the groups. Doing the same comparison between the two periods but taking into account the initial stage, patients who progressed from stage-0 to stage-1 or to stage-2 had higher mean HbA<sub>1c</sub> values during the follow-up period compared to before ( $9.1 \pm 0.1$  vs  $8.4 \pm 0.4\%$ ;  $10.5 \pm 1.3\%$  vs  $10.2 \pm 1.0\%$ , respectively) ( $76 \pm 1.1$  vs  $68 \pm 4.4$  mmol/mol;  $91 \pm 14.2$  vs  $88 \pm 10.9$  mmol/mol) and patients who regressed from stage-1 to stage-0 had lower values during follow-up ( $7.8 \pm 0.2$  vs  $9.1 \pm 1.6\%$ ) ( $62 \pm 2.2$  vs  $76 \pm 17.5$  mmol/mol) although differences didn't reach significance; comparisons for other evolution pares were not possible due to the small numbers.

By the end of the study, mean HbA<sub>1c</sub> levels were higher in patients with LJM compared to those without LJM but the difference was not significant. No differences were found in HbA<sub>1c</sub> levels between males or females with or without LJM. Taking into account the severity of the final stage, in patients with final stage  $\geq 2$  the mean HbA<sub>1c</sub> for all disease duration was higher than in stage-0 patients ( $9.9 \pm 0.9$  vs  $8.6 \pm 0.7\%$ ,  $p=0.01$ ) ( $85 \pm 9.8$  vs  $70 \pm 7.7$  mmol/mol) and than in stage-1 patients ( $9.9 \pm 0.9\%$  vs  $8.2 \pm 0.9\%$ ,  $p=0.01$ ) ( $85 \pm 9.8$  vs  $66 \pm 9.8$  mmol/mol).

### **Relation of LJM to retinopathy and albuminuria**

There was no difference in the prevalence of retinopathy and albuminuria between patients with and without LJM. This proportion was also not different between the progression and regression/no-evolution groups. The relative risk for the presence of microvascular complications showed no significant risk for patients with LJM: RR of retinopathy was 1.6 (95% CI: 0.3-9.6) and RR of albuminuria 1.1 (95% CI: 0.2-6.8).

## **CONCLUSIONS**

Musculoskeletal manifestations associated with type 1 diabetes are frequently under-recognized and overlooked in spite of being quite common and responsible for substantial morbidity (5). LJM is usually asymptomatic and non-disabling but later in the course of the condition it can lead to fixed flexion contractures of the small hand joints, to decreased grip strength and to an impaired dexterity and ability to perform fine hand movements (7; 8; 10). However, the importance of LJM is not just related with the condition itself but also with its presumable association with glycemic control and microvascular complications. LJM pathogenesis can be postulated as the explanation for these associations. There is evidence that persistent hyperglycemia leads to non-enzymatic glycosylation of collagen resulting in accumulation of abnormal cross-linked collagens resistant to degradation that are responsible

for abnormal stiffening of the peri-articular soft tissue; these changes also lead to microvascular abnormalities and vascular ischemia, characteristic changes of diabetic microangiopathy (6; 8; 10). This abnormal glycosylation may be reversible early in the course of the disease or decreased with improved glycemic control but become irreversible later, once cumulative damage to collagen has occurred (24).

Overall prevalence of LJM in our study (85%) was a quite higher than that founded by other reports. We attribute this fact to our definition of LJM and to some of our selection criteria once puberty, age and diabetes duration are associated with higher prevalence of LJM (12; 16). The current study detected any differences between genders. However, unlike the most of the studies, it didn't also detect a significant increased prevalence of LJM with increasing age and diabetes duration, maybe due to the small range of age and diabetes duration of our sample.

Most of the cross-sectional studies have shown no association between LJM and the presence of higher HbA<sub>1c</sub> levels (12; 25-27) but longitudinal studies have confirmed this relation, indicating that the lack of association maybe was due to the use of only a single HbA<sub>1c</sub> value (13; 16; 17; 28). Moreover, two studies in type 1 diabetic patients have shown a decrease in LJM prevalence during a two decades interval, what was attributed to more intensive treatment strategies and improved glycemic control (12; 29). In our study, mean HbA<sub>1c</sub> levels were higher in patients with LJM but, in contrast to the referred longitudinal studies, this result wasn't significant probably due to the small number of our sample. However, when different stages of severity were considered, poor glycemic control was significantly associated with the most severe stages of LJM (stages  $\geq 2$ ) while other patients had a proved better glycemic control. These findings are in agreement with other studies where LJM severity was considered (13; 16). Thus, and considering the reduction in the number of cases with moderate to severe joint limitation also found along with the decrease in LJM prevalence (12; 29), we can

hypothesize that differentiation between different stages of LJM severity might be as or more important than the presence/absence of LJM when considering the role of glycemic control.

Faced with the observation that different patients had a different evolution of their joint mobility during the follow-up period, we hypothesized that differences in joint mobility evolution could be related to differences in glycemic control. Few studies analyze this evolution issue and its relation with other parameters. One study concluded that higher HbA<sub>1c</sub> concentrations are predictive for progression of LJM (28). The possibility of regression/improvement of LJM is also rarely addressed. Only some case reports have shown an improvement and even a complete resolution of LJM along with a decrease in HbA<sub>1c</sub> values (8; 30). In our study, we had similar findings: patients with progression of their initial limitation had poorer glycemic control during the follow-up period than patients whose limitation has improved or at least didn't progressed; these findings appeared to be independent of the initial stage's severity. However, the extent to which an improvement in individual glycemic control would lead to an improvement of LJM or at least could avoid its progression and, on the other hand, a worsening would be responsible for the progression couldn't be clarified: patients who progressed to a severer stage had higher HbA<sub>1c</sub> levels in the follow-up period compared with before in the same way that patients who regressed or maintained the same limitation had lower HbA<sub>1c</sub> levels but differences between the two time periods weren't significant so we can't prove these associations. One explanation for this could be that the degree of glycemic control is more important than its improvement/worsening in LJM evolution; still, we believe that a change in glycemic control can influence LJM evolution.

We didn't detect any significant differences in the prevalence of retinopathy or albuminuria between patients with or without LJM and neither between the different evolution groups. Moreover, there was no significant risk for the presence of these complications in patients with LJM. In spite of our results, several studies have shown that LJM is significantly

associated with both retinopathy and nephropathy in type 1 diabetes (4; 18-20). In a study, the presence of LJM conferred a more than 3-fold increased risk of having microvascular complications (18); a prospective study also concluded that the onset of LJM is associated with a 1.9-fold greater risk of developing microalbuminuria (16). Based on these findings, some authors consider that LJM may be an indicator of the risk of developing these complications while others suggest that in spite of the association, LJM cannot be used as a predictor (25).

We are aware of the several limitations of our study. The small size of our final sample is an important limitation since it may not only limit generalizations of our results but also contribute to the lack of significance of some comparisons. The strict selection criteria and the fact that our sample belongs to a specific clinic population could introduce some selection bias and also limit generalizations but, on the other hand, reduced the variability of the sample and the influence of diabetes duration, age and puberty. A further potential bias is that a different observer undertook 2013 assessments of LJM what could introduce some inter-observer variability. This variability could also account for the observed possibility of LJM evolution. To attenuate this possible bias, the same evaluation methods were carefully followed by both examiners, the abovementioned LJM definition was used and regression and no-evolution groups were grouped for statistical analyzes. In spite of these limitations, we would like to highlight the importance of having the same single observer for all the assessments performed within the same year. Furthermore, this is one of the few studies which describes the longitudinal evolution of LJM and its association with glycemic control.

In summary, severer stages and progression of hand joint limitation are associated with poorer glycemic control in type 1 diabetic adolescents and young adults. Current literature supports that microvascular complications are also associated to chronic hyperglycemia (1) and to LJM (4; 18-20), so we can suppose that a better glycemic control would prevent and delay both LJM and microvascular complications and that LJM's assessment could alert the

physician to the likely presence of retinopathy and nephropathy (8). This evaluation would not, however, substitute their annual screening (16) but could maybe justify doing it sooner than the 5-years of diabetes duration actually defined by the current guidelines (23), especially in pubertal/young adults patients with severe limitation. LJM assessment can be easily done without time-consuming examinations and so should be a part of the follow-up routine of type 1 diabetic patients (8). Nevertheless, larger longitudinal studies with repeated evaluations of LJM using a standardized method are fundamental to evaluate its clinical course, evolution and relation with microvascular complications more fully.

## **ACKNOWLEDGMENTS**

### **Author Contributions**

J.F. collected data, researched on literature, performed the statistical analysis and wrote the manuscript. M.S. collected data, researched on literature and reviewed/edited the manuscript. P.F. reviewed/edited the manuscript.

### **Conflict of Interest**

The authors declare no conflict of interest of any type, inclusive institutional or financial.

## **REFERENCES**

1. Powers AC. Diabetes Mellitus. In *Harrison's Principles of Internal Medicine*. 18 edit. Longo DL, Kasper DL, Jameson JL, Fauci AS, Haase SL, Loscalzo J, Eds. McGraw-Hill Medical, 2012, p. 2968-3003

2. Arkkila PE, Gautier J-F: Musculoskeletal disorders in diabetes mellitus: an update. *Best Pract Res Clin Rheumatol* 2003;17:945-970
3. Papanas N, Maltezos E: The diabetic hand: a forgotten complication? *Journal of diabetes and its complications* 2010;24:154-162
4. Rosenbloom A: Limited joint mobility in insulin dependent childhood diabetes. *Eur J Pediatr* 1990;149:380-388
5. Bhowmik M, Upadhyaya S: Rheumatic manifestations in diabetes mellitus patients. *Apollo Medicine* 2013;
6. Abate M, Schiavone C, Salini V, Andia I: Management of limited joint mobility in diabetic patients. *Diabetes, metabolic syndrome and obesity : targets and therapy* 2013;6:197-207
7. Upreti V, Vasdev V, Dhull P, Patnaik S: Prayer sign in diabetes mellitus. *Indian J Endocrinol Metab* 2013;17:769
8. Somai P, Vogelgesang S: Limited joint mobility in diabetes mellitus: The clinical implications. *J Musculoskel Med* 2011;28:118-124
9. Smith L, Burnet S, McNeil J: Musculoskeletal manifestations of diabetes mellitus. *Br J Sports Med* 2003;37:30
10. Ballantyne J, Hooper G: The hand and diabetes. *Curr Orthop* 2004;18:118-125
11. Rosenbloom AL, Grgic A, Frias JL: Diabetes mellitus, short stature and joint stiffness—a new syndrome. *Pediatric Research* 1974;8:441-441
12. Lindsay JR, Kennedy L, Atkinson AB, Bell PM, Carson DJ, McCance DR, Hunter SJ: Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic population over a 20-year period. *Diabetes care* 2005;28:658-661
13. Garg SK, Chase HP, Marshall G, Jackson WE, Holmes D, Hoops S, Harris S: Limited joint mobility in subjects with insulin dependent diabetes mellitus: relationship with eye and kidney complications. *Archives of disease in childhood* 1992;67:96-99

14. Frost D, Beischer W: Limited joint mobility in type 1 diabetic patients: associations with microangiopathy and subclinical macroangiopathy are different in men and women. *Diabetes care* 2001;24:95-99
15. Campbell RR, Hawkins SJ, Maddison PJ, Reckless JP: Limited joint mobility in diabetes mellitus. *Annals of the rheumatic diseases* 1985;44:93-97
16. Amin R, Bahu T, Widmer B, Dalton R, Dunger D: Longitudinal relation between limited joint mobility, height, insulin-like growth factor 1 levels, and risk of developing microalbuminuria: the Oxford Regional Prospective Study. *Archives of disease in childhood* 2005;90:1039-1044
17. Silverstein JH, Gordon G, Pollock BH, Rosenbloom AL: Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. *J Pediatr* 1998;132:944-947
18. Rosenbloom AL, Silverstein JH, Lezotte DC, Richardson K, McCallum M: Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. *The New England journal of medicine* 1981;305:191-194
19. Montana E, Rozadilla A, Nolla JM, Gomez N, Escofet DR, Soler J: Microalbuminuria is associated with limited joint mobility in type I diabetes mellitus. *Annals of the rheumatic diseases* 1995;54:582-586
20. Arkkila PE, Kantola IM, Viikari JS: Limited joint mobility in type 1 diabetic patients: correlation to other diabetic complications. *Journal of internal medicine* 1994;236:215-223
21. Rosenbloom AL: Limited joint mobility in childhood diabetes: discovery, description, and decline. *The Journal of clinical endocrinology and metabolism* 2013;98:466-473
22. Grgic A, Rosenbloom AL, Weber FT, Giordano B, Malone JJ, Shuster JJ: Joint contracture--common manifestation of childhood diabetes mellitus. *J Pediatr* 1976;88:584-588
23. Executive summary: standards of medical care in diabetes--2014. *Diabetes care* 2014;37 Suppl 1:S5-S13

24. Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW: Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. *The Journal of clinical investigation* 1991;87:1910-1915
25. Arkkila P, Kantola I, Viikari J, Rönnemaa T, Vähätalo M: Limited joint mobility is associated with the presence but does not predict the development of microvascular complications in type 1 diabetes. *Diabetic medicine : a journal of the British Diabetic Association* 1996;13:828-833
26. Clarke CF, Piesowicz AT, Spathis GS: Limited joint mobility in children and adolescents with insulin dependent diabetes mellitus. *Annals of the rheumatic diseases* 1990;49:236-237
27. Kakourou T, Dacou-Voutetakis C, Kavadias G, Bakoula C, Aroni K: Limited joint mobility and lipodystrophy in children and adolescents with insulin-dependent diabetes mellitus. *Pediatric dermatology* 1994;11:310-314
28. Vukovic J, Dumic M, Radica A, Filipovic-Grcic B, Jovanovic V: Risk factors for expression and progression of limited joint mobility in insulin-dependent childhood diabetes. *Acta diabetologica* 1996;33:15-18
29. Infante JR, Rosenbloom AL, Silverstein JH, Garzarella L, Pollock BH: Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. *J Pediatr* 2001;138:33-37
30. Lister DM, Graham-Brown RA, Burden AC: Resolution of diabetic cheiroarthropathy. *British medical journal* 1986;293:1537

## TABLES

**Table 1** - Demographic and clinical characteristics of the sample at the beginning of the study (2007)

<b>Sample size (n)</b>	26
<b>Gender (M/F)</b>	14/12
<b>Age (years)</b>	14.9 ± 1.6
<b>Age of diabetes diagnosis (years)</b>	7.1 ± 3.1
<b>Duration of diabetes (years)</b>	7.5 (5-14)
<b>HbA<sub>1c</sub> (%)*</b>	9.3 ± 1.4
<b>HbA<sub>1c</sub> (mmol/mol)</b>	78 ± 14.2
<b>Patients with retinopathy (n)</b>	0
<b>Patients with albuminuria (n)</b>	2

Data are expressed as means (SD) or median (range) unless stated otherwise. \* Mean of all values recorded on patient's medical files until 2007

**Table 2 - Characteristics of Limited Joint Mobility evolution groups**

	<b>Regression/No-evolution</b>	<b>Progression</b>	<b>p-value</b>
<b>Frequency (n/%)</b>	18 (69%)	8 (31%)	
<b>Gender (M/F)</b>	9/9	5/3	0.7
<b>Duration of diabetes (years)</b>	13.5 (11-20)	13.0 (11-18)	0.8
<b>HbA<sub>1c</sub> (%)*</b>	8.6 ( $\pm$ 1.2)	9.8 ( $\pm$ 1.3)	<u>0.03</u>
<b>HbA<sub>1c</sub> (mmol/mol)</b>	70 $\pm$ 13.1	84 ( $\pm$ 14.2)	
<b>Retinopathy (n/%) †</b>	6 (33.3%)	4 (50%)	0.7
<b>Albuminuria (n/%) †</b>	2 (11.1%)	3 (37.5%)	0.3


Data are expressed as means (SD) or median (range) for the total duration of follow-up. \* Mean of all values recorded during the 6-years follow-up period. † New cases during the follow-up time.

**Table 3** – Characteristics of the sample comparing all subjects with and without Limited Joint Mobility

	<b>With LJM</b>	<b>Without LJM</b>	<b>p-value</b>
<b>Frequency (n/%)</b>	22 (85%)	4 (15%)	
<b>Gender (M/F)</b>	12/10	2/2	1.0
<b>Duration of diabetes (years)</b>	12.5 (11-18)	17 (11-20)	0.1
<b>HbA<sub>1c</sub> (%)*</b>	9.2 ( $\pm$ 1.2)	8.7 ( $\pm$ 0.7)	0.4
<b>HbA<sub>1c</sub> (mmol/mol)</b>			
<b>Retinopathy (n/%) †</b>	9 (41%)	1 (25%)	1.0
<b>Albuminuria (n/%) †</b>	6 (27%)	1 (25%)	1.0

Data are expressed as means (SD) or median (range) for the total duration of the disease. \* Mean of all values recorded until 2013. † Total of cases for the total duration of the disease.

## FIGURES



**Figure 1** Evolution of LMJ during the follow-up time for each initial stage.

## **Agradecimentos**

Agradeço à minha orientadora, Dr.<sup>a</sup> Marta João Rodrigues Silva, pela sugestão do tema e pela confiança, interesse e disponibilidade sempre demonstradas. Agradeço ainda pela revisão e leitura pormenorizada do trabalho final.

Agradeço também à minha coorientadora, Doutora Paula Isabel Marques Simões de Freitas, por toda a sua disponibilidade e pela revisão e leitura crítica e construtiva do trabalho final.

Por fim, agradeço ao meu colega Luís Pinto pela disponibilidade para esclarecer algumas dúvidas relativas à análise estatística.

# **ANEXOS**

## Anexo 1

### *Diabetes Care* Instructions for Authors

*Last updated on November 19, 2013.*

**Beginning with manuscripts submitted after Jan. 1, 2013, *Diabetes Care* requires authors to report HbA1c levels in both traditional, DCCT-derived units (as %) and SI, IFCC-recommended units (as mmol/mol). Authors should use the NGSP converter for HbA1c, available at <http://www.ngsp.org/convert1.asp>, to calculate HbA1c values as both % and mmol/mol. (Please note the additional link available for converting standard deviations.) Values should first be reported as %, followed by the mmol/mol equivalent in parentheses.**

#### **1. ABOUT THE JOURNAL**

#### **2. POLICIES**

#### **3. EDITORIAL OFFICE CONTACT INFORMATION**

#### **4. FORMS AND REQUIREMENTS**

#### **5. MANUSCRIPT CATEGORIES**

#### **6. MANUSCRIPT FORMAT AND STYLE**

#### **7. SUBMITTING A MANUSCRIPT**

#### **8. ACCEPTED MANUSCRIPTS**

#### **9. FINANCIAL OBLIGATIONS**

*Diabetes Care* takes only online manuscript submissions. The submission site can be found at <http://mc.manuscriptcentral.com/diabetescare>. Please read all instructions carefully. Failure to follow the submission instructions may delay the review process.

#### **1. ABOUT THE JOURNAL**

*Diabetes Care* is a journal for the health care practitioner that is intended to increase knowledge, stimulate research, and promote better management of people with diabetes. To achieve these goals, the journal publishes Original Articles on human studies in the following categories:

- 1) Clinical Care/Education/Nutrition/Psychosocial Research
- 2) Epidemiology/Health Services Research
- 3) Pathophysiology/Complications
- 4) Cardiovascular and Metabolic Risk

The journal also publishes clinically relevant review articles, letters to the editor, and commentaries. Topics covered are of interest to clinically oriented physicians, researchers,

epidemiologists, psychologists, diabetes educators, and other health professionals. The journal does not publish descriptions of study designs without data, papers on in vitro studies, or studies involving animals.

The editor-in-chief of *Diabetes Care*, William T. Cefalu, MD, began his term with the January 2012 issue. Dr. Cefalu's editorial team began reviewing first submissions on July 1, 2011.

## **2. POLICIES**

The American Diabetes Association's Publications Policy Committee follows the recommendations of the International Committee of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), and the Committee on Publication Ethics (COPE) for guidance on policies and procedures related to publication ethics. The policies for *Diabetes Care* have been adopted from those three advisory bodies and, where necessary, modified and tailored to meet the specific content, audiences, and aims of *Diabetes Care*. Comprehensive information related to the editorial and ethical policies of *Diabetes Care* can be found in **Publication Policies and Procedures for *Diabetes Care***.

The Association's Publications Policy Committee or Subcommittee on Ethical Scientific Publications will consider on a case-by-case basis policies that are not addressed in the policies document. Frequently referenced segments of the document appear below.

**2.1** *Diabetes Care* publishes only material that has not been published previously (either in print or electronically) and is not under consideration for publication elsewhere, with the exception of an abstract that is less than 400 words in length. Prior presentation of data (e.g., at a scientific meeting or via webcast) does not preclude publication in *Diabetes Care*, but should be disclosed in the Acknowledgments of the paper and in the author's comments to the editor upon manuscript submission. All submissions to the journal will be scanned for possible duplicate or prior publication using the CrossCheck/iThenticate plagiarism detection system ([www.ithenticate.com](http://www.ithenticate.com)). Any article that eclipses a certain similarity threshold with another article will be closely reviewed by ADA. Authors who submit previously published work to the journal will be banned from submitting future manuscripts to the journal, and their funding body and/or institution will be notified. All contributions, including solicited articles and symposia, are critically reviewed by the editors and/or invited referees. Reviewers' comments are usually provided to the authors. The decision of the editors is final.

**2.2. Prepublication of Research Articles.** To make new research readily available to subscribers, *Diabetes Care* publishes original research articles online ahead of print before the print/online issue becomes available. Online Ahead of Print articles are citable by their unique DOI (digital object identifier). DOIs for *Diabetes Care* articles begin with 10.2337, followed by the article number assigned

when the manuscript was submitted online via the manuscript submission system. (e.g., 10.2337/dc13-1234)

*Example:* Kohler C, Norton H, Such V, Baldino N: How to cite a prepublished article in ADA journals.

Diabetes Care 10.2337/dc13-1234. Accessed [insert date]

**2.3. Embargo Policy.** If you are interested in reporting on a *Diabetes Care* article published online ahead of print, please read the article embargo policy for specific instructions and conditions. Articles that were not prepublished are embargoed until they appear in a final issue of *Diabetes Care* Online.

**2.4. Public Access Policy.** As a courtesy to authors, the final print versions of articles funded by NIH will be deposited in PubMed Central (PMC) at no additional cost. In compliance with NIH's policy, these articles will appear on PMC 12 months after print publication in *Diabetes Care*. All articles, regardless of funding body, are delivered to PubMed for inclusion in the PubMed index. Full-text HTML versions of all articles are freely accessible on *Diabetes Care* Online ([care.diabetesjournals.org](http://care.diabetesjournals.org)) 6 months after the print publication date, and PDF content becomes freely accessible 12 months after the print publication date. Authors may submit the accepted version of their *manuscript* to their funding body's repository immediately upon acceptance.

### 3. EDITORIAL OFFICE CONTACT INFORMATION

Diabetes Care Editorial Office

5110 Commerce Square Dr., Suite G

Indianapolis, IN 46237

phone: (317) 354-1508, ext 1782 fax: (317) 859-3592

e-mail: [diabetescare@diabetes.org](mailto:diabetescare@diabetes.org)

Lyn Reynolds, Director, Editorial Office

Shannon Potts and Jane Lucas, Peer Review Managers

Rita Summers, Editorial Assistant

Joan Garrett, Editorial Secretary

Rachel Castillo, Editorial Secretary

## 4. FORMS AND REQUIREMENTS

**4.1.** The **Manuscript Submission Form** addresses ADA's policies on 1) originality and authorship, 2) copyright assignment, and 3) potential conflict of interest and outlines the Association's permission policies related to reuse and post prints. ADA will also accept ICMJE's Uniform Disclosure Form for Potential Conflicts of Interest. The corresponding author may complete the form on behalf of all authors. Corresponding authors are encouraged to scan and upload the form to the manuscript submission site with their article files. If this is not possible, the corresponding author may fax (317-859-3592) or e-mail (EditorialOffice@diabetes.org) the completed form for all authors to the Editorial Office immediately after submission. Submissions will not be considered complete until the form has been received.

**4.1.2. Statement of Originality and Authorship.** *Diabetes Care* subscribes to the requirements stated in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals that authorship implies substantial contributions to conception and design or analysis and interpretation of data and drafting of the article or critical revision for important intellectual content. The editor reserves the right to query authorship contribution.

**4.1.3. Copyright Assignment.** The American Diabetes Association holds the copyright on all material appearing in *Diabetes Care*, unless the content is produced by an employee of the U.S. government as part of the authors' official duties. The corresponding author must check the appropriate box on the Manuscript Submission Form, which transfers copyright to the ADA in accordance with the Copyright Revision Act of 1976.

**4.1.4. Conflict of Interest.** Please read the ADA Policy Statement on Duality of Interest and check the box for Potential Conflict of Interest Disclosure on the Manuscript Submission Form. In addition to completing the Manuscript Submission Form, all submitted papers must include a conflict-of-interest statement for all authors in the Acknowledgments section. If authors have no relevant conflict of interest to disclose, this should be indicated in the Acknowledgments section. Relevant conflict of interest (or lack thereof) should also be disclosed in the authors' comments to the editor during the submission process.

**4.5. Author Contributions.** Authors are required to include a paragraph in the Acknowledgments section listing each author's *Example*: "C.K. researched data. L.R. wrote the manuscript and researched data. H.N. reviewed/edited the manuscript. V.S. contributed to the discussion and reviewed/edited the manuscript. N.B. researched data and contributed to discussion. V.G. wrote the manuscript."

**4.6. Writing Groups.** The names of members of writing groups should be listed at the end of the paper in the Acknowledgments section (if no more than two or three short paragraphs) or in a separate supplemental online-only file.

**4.7. Affiliations.** Institutional and/or employment affiliations of all authors should be listed on the title page of the manuscript. In addition, when citing “editorial assistance” or help provided by a colleague, authors are required to list the employer/institution with which that colleague is affiliated.

*Example:* “The authors acknowledge the editorial assistance of Mark Smith, Global Informatics, Inc.”; “The authors thank Mark Smith, Global Informatics, Inc., for help with preparing the manuscript.”

**4.8. Reuse.** Authors are permitted to reuse portions of their ADA-copyrighted work in their own work, including tables and figures, and to reuse portions or all of their ADA-copyrighted work for lecture or classroom purposes, provided that the proper citation and copyright information is given.

**4.9. Post-Prints.** Authors are permitted to submit the accepted version of their *manuscript* to their funding body or institution for inclusion in that funding body or institution’s database, archive, or repository, or to post the accepted version on their personal Web site. These manuscripts may be made freely accessible to the public upon acceptance, provided that the following two conditions are observed: First, post-prints must include the following statement of provenance and, once the final version has been published in the journal, a link to the final published version of the paper on the journal's Web site:

This is an author-created, uncopyedited electronic version of an article accepted for publication in *Diabetes Care*. The American Diabetes Association (ADA), publisher of *Diabetes Care*, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of *Diabetes Care* in print and online at <http://care.diabetesjournals.org>.

Second, the version of the manuscript deposited or posted must be identical to the final accepted version, with the exception of the addition of the above statement and any changes necessary to correct errors. Authors may make changes to the posted version to correct mistakes or may issue an erratum at any time. However, the final published version of the manuscript may not be deposited, posted, or later substituted for the post-print.

## 5. MANUSCRIPT CATEGORIES

See Section 6, Manuscript Format and Style, for detailed instructions on formatting documents.

**5.1. Original Articles.** Original Articles should be arranged in the following order: title page, structured abstract, introduction (no heading), “Research Design and Methods,” “Results,” “Conclusions,” “Acknowledgments,” “References,” tables, and figure legends. A **structured abstract** is required for all Original Articles. Abstracts for an Original Article should not exceed 250 words. (This is not to be confused with abstracts submitted to the Annual Scientific Meeting, for which the word limit is higher.)

The abstract must be self-contained and clear without reference to the text and should be written for a general journal readership. The abstract format should include four sections: “Objective” (the purpose or hypothesis of study), “Research Design and Methods” (the basic design, setting, number of participants and selection criteria, treatment or intervention, and methods of assessment), “Results” (significant data found), and “Conclusions” (the validity, limitations, and clinical applicability of the study and its results).

The **word count limit** for Original Articles is 4,000 words, excluding words in tables, table legends, figure legends, title page, acknowledgments, and references. In addition, an original article is limited to a combination of 4 tables and figures. **References** are limited to 40 citations.

A conflict-of-interest statement for all authors must be included in the Acknowledgments section of the main document, which should follow the main text and precede the references. If there are no relevant conflicts of interest to disclose, authors should indicate as such in the Acknowledgments section.

## **6. MANUSCRIPT FORMAT AND STYLE**

Articles must be in clear and understandable English. Non-native English authors are encouraged to seek the assistance of an English-proficient colleague, or a communications agency, such as American Journal Experts, to help improve the clarity and readability of a paper before it is submitted to the journal. For specific information on the parameters and limits for various manuscript categories (e.g., section headings, word limits, etc.), see section 5, Manuscript Categories.

**6.1. Title Page.** Every manuscript, regardless of article type, must have an accompanying title page. In addition to the title, the title page should include a short running title (less than 47 characters and spaces combined); the first name, middle initial, last name, and highest academic degree of each author; affiliation (in English) of each author during the time the study was conducted; name, current address, telephone number, fax number, and e-mail address of the corresponding author; and the word count and number of tables and figures.

**6.2. Main Document.** The main document file includes the title page, abstract, main text, acknowledgements, figure legends, references, and tables. Please do not use headers, footers, or endnotes in your paper. The Main Document should be in Word document format (not as a PDF). This will allow our Editorial Office to verify the word count and our production staff to turn your paper (if accepted) into an article.

**6.3. Text Composition.** Articles should be written in clear, concise English following the recommendations for scientific writing found in *Scientific Style and Format*, the Council of Science Editors (CSE) style manual (7th ed., 2006, Reston, VA, Council of Science Editors). All accepted manuscripts will be edited according to the CSE style manual and *The Chicago Manual*

of *Style* (16th ed., 2010, Chicago, IL, The University of Chicago Press) by ADA professional publications staff. The authors are responsible for all statements made in their articles or editorials, including any editing changes made by staff. Proof pages will be sent to the corresponding author and should be read carefully. The designations *type 1 diabetes* and *type 2 diabetes* should be used when referring to the two major forms of diabetes. Abbreviations for diabetes, such as T2D for *type 2 diabetes*, should not be used. The term *diabetic* should not be used as a noun. All manuscripts should be double-spaced, in Arial or Times New Roman 12-point font, and saved as a .doc, .txt, or .rtf file. In addition, please do not "lock" or "page protect" your document, and avoid using footnote and endnote functions.

**6.4. Abbreviations and Units.** Abbreviations should be used only when necessary, e.g., for long chemical names (HEPES), procedures (ELISA), or terms used throughout the article. See the list of abbreviations that need not be defined; all others must be defined at first use. Abbreviate units of measure only when used with numbers. Abbreviations may be used in tables and figures. The CSE style manual contains lists of standard scientific abbreviations. Clinical laboratory values and units should be in Système International (SI) form. Kilocalories should be used rather than kilojoules. HbA1c values should be dually reported as "% (mmol/mol)." Please use the NGSP's HbA1c converter at <http://www.ngsp.org/convert1.asp> to calculate HbA1c values as both % and mmol/mol.

**6.5. Font.** Text, including title and author names, should be in 12-point Arial or Times New Roman. Please avoid using boldface font. Text in tables should be no smaller than 10-point font.

**6.6. Margins.** Margins should be 1" at the top and bottom and 1" on the left and right sides.

**6.7. Acknowledgments.** The acknowledgments are located after the main text and before the reference list. Acknowledgments should contain the author contributions paragraph, brief statements of assistance, the guarantor's name (person[s] taking responsibility for the contents of the article), funding/financial support, and reference to prior publication of the study in abstract form, where applicable.

**6.8. References.** The reference list should go at the end of the document, after the main text and acknowledgments (if applicable) and before the tables. Original Articles are limited to 40 references. Letters are allowed 5 references. Review Articles are allowed 60 references, and meta-analyses should have no more than 40 references. Reference numbers in the text should appear in chronological order in normal type and in parentheses [e.g., "In the study by Norton et al. (23)..."]. Please do not use the footnote or endnote function to cite studies or create a reference list. A reference manager must have the ability to customize the display of references. For example, the reference application should have the option to list the references at the end of the paper, as opposed to listing the references as endnotes or footnotes at the bottom of each page, and should not embed the list in the text as a series of endnotes/footnotes. When using a reference manager (e.g., Thomson's EndNote Reference Program),

don't forget to generate the list as a bibliography in a style suitable to *Diabetes Care*, and then save and submit as the final step to creating the references. Otherwise, references should be manually inserted.

All authors must be listed by first initials and last name in each reference, and please provide inclusive page numbers. Journal titles should be abbreviated according to the National Library of Medicine's List of Journals Indexed for Medline; for unlisted journals, please provide complete journal titles. Material in press may be cited, but copies of such material may be requested. Authors are responsible for the accuracy of the references. Click [here](#) for examples of how references should be formatted.

**6.9. Supplemental Data.** Non-essential tables, figures, and/or videos may accompany articles as online-only supplemental files, but authors are asked to include a comment to the editor at the time of manuscript submission that explains the rationale and justification for submitting and possibly posting the supplemental materials. All online-only supplementary files should be combined in one document file whenever possible and uploaded during the submission process. The file must be clearly labeled as "Online-Only Supplemental Material" (tables, figures, etc.) or "Online Supplemental Video." In addition, supplemental online-only files must be referenced in the main text of the manuscript at least once (e.g., "Supplemental Table S1"). All online-only supplemental files are subject to review, but such files will not be copyedited or proofread by ADA production staff. As such, authors are encouraged to review their supplemental files carefully before submitting them. Lists that include names of **principal investigators or writing groups** may also be submitted as online-only supplements if they exceed 150 words. Otherwise, the names of principal investigators or writing groups should be listed in an appendix at the end of the main document, before the references.

**6.10. Tables.** Each table should be inserted on a separate page at the end of the document with the table number, title, and legend indicated. Table legends should be inserted below the table and should not be included inside the table. Tables should be created using Word and the "Insert Table" command. Please use Arial or Times New Roman font, no smaller than 10-point. Tables with internal divisions are not allowed (Tables 1A and B) and should be submitted as individual tables (Tables 1 and 2). Please avoid using shading within a table. If a table includes data that require explanation in the legend, apply the following sequence of symbols, from top to bottom, left to right: \*, †, ‡, §, ||, ¶, #, \*\*, ††, ‡‡.

**6.11. Figures.** *Diabetes Care* uses digital publishing methods throughout the journal production process. If your article is accepted, it will be published in both the print and online journal. The following sections provide information on how to format your figures to ensure the best possible reproduction of your images.

**Size.** Figures should be produced at the size they are to appear in the printed journal. Please make sure your figures will fit in one, two, or three columns in width. Multi-paneled figures should be assembled in a layout that leaves the least amount of blank space.

1 column = 13 picas wide, 2.2 in, 5.6 cm

2 columns = 28 picas wide, 4.6 in, 11.7 cm

3 columns = 41 picas, 6.8 in, 17.3 cm

**Font.** At 100% size, fonts should be 8-10 points and used consistently throughout all figures.

**Text.** Information on the axes should be succinct, using abbreviations where possible, and the label on the y-axis should read vertically, not horizontally. Key information should be placed in any available white space **within** the figure; if space is not available, the information should be placed in the legend. In general, figures with multiple parts should be marked A, B, C, etc., with a description of each panel included in the legend rather than on the figure.

**Line and bar graphs.** Lines in graphs should be bold enough to be easily read after reduction, as should all symbols used in the figure. Data points are best marked with the following symbols, again assuring that they will be readily distinguishable after reduction: In the figure legend, please use words rather than the symbols; e.g., "black circles = group 1; white squares = group 2; black bars = blood glucose; white bars = C-peptide." Bars should be black or white only, unless more than two datasets are being presented; additional bars should be drawn with clear bold hatch marks or stripes, **not** shades of gray. Line or bar graphs or flow charts with text should be created in black and white, **not** shades of gray, which are difficult to reproduce in even tones.

**Formatting digital figures files for print and online reproduction.** To meet ADA's quality standards for publication, it is important to submit digital art that conforms to the appropriate resolution, size, color mode, and file format. Doing so will help to avoid delays in publication and maximize the quality of images, both online and in print. Please refer to ADA's Digital Art Guidelines when preparing your files. If you are unable to provide files that meet the specifications outlined in the Guidelines, you may submit your original source files (files from the program in which they were originally created).

**Reproductions.** If materials (e.g., figures and/or tables) are taken from other sources, the author must provide written permission for reproduction from the original publisher and author at the time of submission. In addition, the source should be cited at the end of the figure legend. For more information, refer to Permissions: Help for Authors.

**Digital image manipulation.** The American Diabetes Association has adopted the statement developed by the *Journal of Cell Biology* as its policy on the manipulation of digital images:

"No specific feature within an image may be enhanced, obscured, moved, removed, or introduced. The grouping of images from different parts of the same gel, or from different gels, fields, or exposures must be made explicit by the arrangement of the figure (i.e., using dividing lines) and in the text of the figure legend. Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the whole image and as long as they do not obscure, eliminate, or misrepresent any information present in the original, including backgrounds. Without any background information, it

is not possible to see exactly how much of the original gel is actually shown. Non-linear adjustments (e.g., changes to gamma settings) must be disclosed in the figure legend."

All digital images in manuscripts accepted for publication will be scanned using image forensics software for any indication of improper manipulation. Cases of questionable or inappropriate image alterations will be referred to the Association's Subcommittee on Ethical Scientific Publications (ESP). The ESP may request the original data from the authors for comparison to the prepared figures. If the authors fail to provide the original data, the acceptance of the manuscript will be revoked. Cases of deliberate misrepresentation of data will result in revocation of acceptance, and will be reported to the corresponding author's home institution and/or funding agency as appropriate. For examples of what constitutes improper digital manipulation (as well as other forms of scientific misconduct), ADA encourages authors to refer to the 2006 editorial by the *Journal of Clinical Investigation* titled "Stop Misbehaving!" In addition, authors are encouraged to refer to Adobe's white paper on using Photoshop CS3 Extended in biomedical imaging. The paper provides useful information on maintaining image integrity, editing nondestructively, and the medical and scientific image workflow.